Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 9, 1996, Pages 3295-3298

  Prigeon, Ronald L ^a,b   Jacobson, Randall K ^a   Porte Jr , Daniel ^a   Kahn, Steven E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLIPIZIDE; PROINSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CLINICAL ARTICLE; DIET RESTRICTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HORMONE RESPONSE; HUMAN; IMMUNOREACTIVITY; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; ARGININE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PROINSULIN; SULFONYLUREA COMPOUNDS;

EID: 0029834356     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.9.3295     Document Type: Article

References (25)

1. Duckworth WC, Kitabchi AE, Heinemann M. 1972 Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med. 53:418-427.
2. Pfeifer MA, Halter JB, Judzewitsch RG, et al. 1984 Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man. Diabetes Care. 7:25-34.
3. Elkeles R, Heding L, Paisey R. 1982 The long-term effects of chlorpropamide on insulin, C-peptide, and proinsulin secretion. Diabetes Care. 5:427-429.
4. Cohen RM, Nathan DM, Clements RS. 1992 Hyperproinsulinemia in type II diabetes. Diabetes Care. 15:723-724.
5. Lebovitz HE. 1990 Oral hypoglycemic agents. In: Rifkin H, Porte Jr D, eds. Diabetes mellitus: theory and practice, 4th ed. New York: Elsevier; 554-574.
6. Wajchenberg BL, Tereza A, Santomauro MG, Porrelli RN. 1993 Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Res Clin Pract. 20:147-154.
7. Welch S, Gebhart SSP, Bergman RN, Phillips LS. 1990 Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 71:1508-1518.
8. Finegood DT, Hramiak IM, Dupre J. 1990 A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab. 70:1538-1549.
9. Saad MF, Anderson RL, Laws A, et al. 1994 A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes. 43:1114-1121.
10. Palmer JP, Walter RM, Ensinck JW. 1975 Arginine-stimulated acute phase of insulin and glucagon secretion in normal man. Diabetes. 24:735-740.
11. Prigeon RL, Kahn SE, Porte Jr D. 1994 Reliability of error estimates from the minimal model: implications for measurements in physiological studies. Am J Physiol 266:279-E286.
12. Morgan DR, Lazarow A. 1963 Immunoassay of insulin: two antibody system: plasma insulin levels of normal, subdiabetic, and diabetic rats. Diabetes. 12:115-126.
13. Ward WK, Paquette TL, Frank BH, Porte Jr D. 1986 A sensitive radioimmunoassay for human proinsulin with sequential use of antisera to C-peptide and insulin. Clin Chem. 32:728-733.
14. Duckworth WC, Solomon SS, Kitabchi AE. 1972 Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol Metab. 35:585-591.
15. Mako ME, Starr JI, Rubenstein AH. 1977 Circulating proinsulin in patients with maturity onset diabetes. Am J Med. 63:865-869.
16. Røder ME, Kahn SE, Porte Jr D. 1995 Disproportionate hyperproinsulinemia reflects the degree of B-cell dysfunction in NIDDM [Abstract]. Diabetes. 44(Suppl 1):156A.
17. U.K. Prospective Diabetes Study Group. 1995 U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 44:1249-1258.
18. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte Jr D. 1984 Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest. 74:1318-1328.
19. Chu PC, Conway MJ, Krouse HA, Goodner CJ. 1968 The pattern of response of plasma insulin and glucose to meals and fasting during chlorpropamide therapy. Ann Intern Med. 68:757-769.
20. Judzewitsch RG, Pfeifer MA, Best JD, Halter JB, Porte Jr D. 1982 Chronic chlorpropamide therapy of noninsulin dependent diabetics augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. J Clin Endocrinol Metab. 55:321-328.
21. Tsalikian E, Dunphy TW, Bohannon NV, et al. 1977 The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal. Diabetes. 26:314-321.
22. Pfeifer MA, Halter JB, Beard JC, Judzewitsch R, Porte Jr D. 1982 Insulin responses to nonglucose stimuli in noninsulin dependent diabetes mellitus during a tolbutamide infusion. Diabetes. 31:154-159.
23. Kahn SE, Prigeon RL, McCulloch DK, et al. 1994 The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes. 43:587-592.
24. Kahn SE, Beard JC, Schwartz MW, et al. 1989 Increased B-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 38:562-568.
25. Røder ME, Dinesen B, Houssa P, Hartling SG, Sodoyez-Goffaux F, Binder C. 1995 Elevated intact proinsulin in NIDDM is not due to obesity [Abstract]. Diabetologia 38:A114.